Amneal Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw unusually large options trading activity on Monday. Investors purchased 2,563 call options on the stock. This is an increase of approximately 719% compared to the typical daily volume of 313 call options.

Analyst Ratings Changes

AMRX has been the subject of several recent analyst reports. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Truist Financial raised their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a research note on Friday, September 6th. Finally, Piper Sandler increased their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Amneal Pharmaceuticals Trading Down 0.6 %

AMRX stock traded down $0.05 during mid-day trading on Monday, hitting $7.73. The stock had a trading volume of 72,130 shares, compared to its average volume of 1,376,732. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48. The company has a fifty day moving average of $8.42 and a 200 day moving average of $7.94. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -11.37 and a beta of 1.12.

Insider Transactions at Amneal Pharmaceuticals

In other news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 26.56% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Rothschild Investment LLC acquired a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $26,000. Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $37,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $42,000. nVerses Capital LLC bought a new stake in Amneal Pharmaceuticals in the second quarter worth $62,000. Finally, Xponance Inc. acquired a new position in Amneal Pharmaceuticals during the second quarter worth $65,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.